Abstract
A series of aminoalkanol and amino acid derivatives of trans-cinnamic acid as well as aminoalkanol derivatives of α-phenylcinnamic acid was synthesized and evaluated for anticonvulsant activity. All compounds were verified in mice after intraperitoneal (i.p.) administration in maximal electroshock (MES) and subcutaneous pentetrazole (ScMet) induced seizures as well as neurotoxicity assessment. Six of them showed protection in MES at 100 mg/kg b.w. and one at 300 mg/kg b.w. For selected derivatives evaluation in ScMet test in rats after per os (p.o.) administration, 6-Hz test in mice and pilocarpine-induced status in rats were performed. The results are quite encouraging and further modification of the structures might lead to discovering new potential anticonvulsants.
Keywords: Amino acid derivatives, Aminoalkanol derivatives, Anticonvulsant, MES, ScMet, Synthesis, Cinnamic acid derivatives, trans-cinnamic, aminoalkanol, intaperitoneal, pilocarpine, subcutaneous pentetrazole (ScMet), trans-a-phenylcinnamic, Oxytropis pseudoglandulosa, toluene/K2CO3, acylation, polarimeter
Letters in Drug Design & Discovery
Title: Preliminary Evaluation of Anticonvulsant Activity of Some Aminoalkanol and Amino Acid Cinnamic Acid Derivatives
Volume: 9 Issue: 1
Author(s): Agnieszka Gunia, Anna M. Waszkielewicz, Marek Cegla and Henryk Marona
Affiliation:
Keywords: Amino acid derivatives, Aminoalkanol derivatives, Anticonvulsant, MES, ScMet, Synthesis, Cinnamic acid derivatives, trans-cinnamic, aminoalkanol, intaperitoneal, pilocarpine, subcutaneous pentetrazole (ScMet), trans-a-phenylcinnamic, Oxytropis pseudoglandulosa, toluene/K2CO3, acylation, polarimeter
Abstract: A series of aminoalkanol and amino acid derivatives of trans-cinnamic acid as well as aminoalkanol derivatives of α-phenylcinnamic acid was synthesized and evaluated for anticonvulsant activity. All compounds were verified in mice after intraperitoneal (i.p.) administration in maximal electroshock (MES) and subcutaneous pentetrazole (ScMet) induced seizures as well as neurotoxicity assessment. Six of them showed protection in MES at 100 mg/kg b.w. and one at 300 mg/kg b.w. For selected derivatives evaluation in ScMet test in rats after per os (p.o.) administration, 6-Hz test in mice and pilocarpine-induced status in rats were performed. The results are quite encouraging and further modification of the structures might lead to discovering new potential anticonvulsants.
Export Options
About this article
Cite this article as:
Gunia Agnieszka, M. Waszkielewicz Anna, Cegla Marek and Marona Henryk, Preliminary Evaluation of Anticonvulsant Activity of Some Aminoalkanol and Amino Acid Cinnamic Acid Derivatives, Letters in Drug Design & Discovery 2012; 9 (1) . https://dx.doi.org/10.2174/157018012798192982
DOI https://dx.doi.org/10.2174/157018012798192982 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Importance of P-gp PET Imaging in Pharmacology
Current Pharmaceutical Design Transcriptional Dys-regulation in Anxiety and Major Depression: 5-HT1A Gene Promoter Architecture as a Therapeutic Opportunity
Current Pharmaceutical Design Borna Disease Virus (BDV): Neuropharmacological Effects of a CNS Viral Infection
Current Neuropharmacology The Role of Newer Antiglutamatergic Agents as Mood-Stabilizers in Bipolar Disorder
Current Drug Targets Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Triggers of Cell Death in the Developing Brain
Current Pediatric Reviews Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Targets for the Treatment of Comorbidities Associated with Epilepsy
Current Molecular Pharmacology Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA Drug Delivery Across the Blood-Brain Barrier
Current Nanoscience Pediatric Catatonia: Updating An Old Syndrome in Young People
Current Psychiatry Reviews Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets The Ability of MEAs Containing Cultured Neuroglial Networks to Process Information
Current Bioinformatics Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Current Gene Therapy Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications
Current Neuropharmacology Recent Developments of the PET Imaging Agents for Metabotropic Glutamate Receptor Subtype 5
Current Topics in Medicinal Chemistry